Does furosemide cause gynaecomastia? This is a question that arises in clinical practice, given that furosemide — a commonly prescribed loop diuretic used in heart failure, chronic kidney disease, and liver cirrhosis — is occasionally cited alongside drug-induced gynaecomastia. However, the direct evidence linking furosemide to gynaecomastia is limited, and it is not listed as an adverse effect in the UK Summary of Product Characteristics. Understanding the broader hormonal context, co-prescribed medicines, and underlying conditions is essential before attributing breast tissue changes in males to furosemide alone.

Furosemide and Gynaecomastia: What the Evidence Shows

Gynaecomastia is not listed as an adverse effect of furosemide in its UK SmPC, and direct clinical evidence linking furosemide to gynaecomastia is limited; pharmacovigilance signals exist but do not confirm causality.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — can arise from a wide range of causes, including hormonal imbalances, underlying medical conditions, and certain medicines. Furosemide, a widely prescribed loop diuretic used to manage fluid overload in conditions such as heart failure, chronic kidney disease, and liver cirrhosis, is occasionally cited in discussions about drug-induced gynaecomastia. However, the direct evidence linking furosemide specifically to gynaecomastia is limited and not firmly established in the clinical literature.

Importantly, gynaecomastia is not listed as an adverse effect in the UK Summary of Product Characteristics (SmPC) for furosemide, as published on the Electronic Medicines Compendium (EMC). Unlike medicines such as spironolactone or digoxin, furosemide is generally considered a low-risk agent in this regard. Adverse drug reaction (ADR) signals in pharmacovigilance — including those captured through the MHRA Yellow Card scheme — typically arise from case reports and observational data rather than randomised controlled trials, and occasional breast-related reports have been noted for furosemide in such databases; however, these signals do not establish a confirmed causal relationship.

In clinical practice, when a patient taking furosemide develops gynaecomastia, clinicians are advised to consider the full clinical picture — including co-prescribed medicines, underlying conditions, and hormonal status — before attributing the symptom to furosemide alone. A thorough medication review is always warranted. If you suspect furosemide or any other medicine is causing a side effect, you can report this directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

How Loop Diuretics May Affect Hormone Balance

Furosemide may theoretically influence hormonal balance via RAAS activation, but this pathway has not been demonstrated to cause gynaecomastia; co-prescribed spironolactone is a far more likely cause.

To understand why furosemide might theoretically contribute to gynaecomastia, it is helpful to consider how loop diuretics interact with the body's hormonal systems. Furosemide works by inhibiting the sodium-potassium-chloride (Na⁺-K⁺-2Cl⁻) co-transporter in the thick ascending limb of the loop of Henle in the kidney, promoting the excretion of sodium, chloride, and water to reduce fluid overload. While this mechanism is primarily renal, diuretics can indirectly influence hormonal pathways.

One hypothetical mechanism involves the renin-angiotensin-aldosterone system (RAAS). Furosemide-induced volume depletion can activate the RAAS, leading to elevated aldosterone levels. It has been suggested, speculatively, that prolonged hormonal shifts within this system could have downstream effects on sex hormone balance; however, this pathway has not been demonstrated to cause gynaecomastia in clinical studies and should be regarded as unproven.

Of greater clinical relevance is the fact that furosemide is frequently co-prescribed with spironolactone, a potassium-sparing diuretic that is a well-established cause of gynaecomastia due to its anti-androgenic properties, as documented in the BNF and the spironolactone SmPC. In such cases, spironolactone is far more likely to be the causative agent, and clinicians should prioritise this distinction when reviewing potential drug-related breast changes.

Additionally, in patients with liver cirrhosis — a condition for which furosemide is commonly prescribed — impaired hepatic metabolism of oestrogens is itself a well-recognised cause of gynaecomastia, as noted in NICE CKS guidance on gynaecomastia. This makes it particularly difficult to isolate any contribution from furosemide in this patient group.

Other Medicines and Conditions Linked to Gynaecomastia

Medicines account for an estimated 10–25% of gynaecomastia cases; the most strongly implicated include spironolactone, digoxin, anti-androgens, and GnRH analogues, alongside conditions such as liver cirrhosis and hypogonadism.

Gynaecomastia has a broad differential diagnosis, and medicines are responsible for an estimated 10–25% of cases (NICE CKS: Gynaecomastia). Understanding the wider landscape of drug-induced and condition-related gynaecomastia helps place the furosemide question in proper context. Some of the most commonly implicated medicines include:

• Spironolactone — acts as an androgen receptor antagonist and is one of the most frequent drug causes

• Digoxin — has oestrogen-like activity

• Cimetidine — an H2 receptor antagonist with anti-androgenic effects

• Anabolic steroids and testosterone — can be converted peripherally to oestradiol

• Anti-androgens (e.g., bicalutamide, flutamide) — used in prostate cancer; a well-recognised cause

• 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) — used for benign prostatic hyperplasia and hair loss; associated with gynaecomastia

• GnRH analogues (e.g., goserelin, leuprorelin) — used in prostate cancer; cause gynaecomastia via androgen suppression

• Some antipsychotics and antidepressants — may elevate prolactin levels

• Certain antiretrovirals (e.g., efavirenz) — associated with gynaecomastia in some patients

• Chemotherapy agents — particularly alkylating agents

• Proton pump inhibitors — occasional case reports and pharmacovigilance signals exist, but evidence of causality is limited and uncertain

Beyond medicines, several medical conditions are strongly associated with gynaecomastia. Liver cirrhosis impairs oestrogen metabolism, leading to relative oestrogen excess. Chronic kidney disease and hyperthyroidism can disrupt the androgen-to-oestrogen ratio. Hypogonadism, whether primary or secondary, reduces testosterone production, tipping the hormonal balance towards oestrogen dominance. Testicular tumours, including Leydig cell tumours and germ cell tumours, can secrete oestrogens or human chorionic gonadotrophin (hCG) and must be excluded in any new presentation of gynaecomastia.

Physiological gynaecomastia also occurs during neonatal life, puberty, and older age, and does not require treatment in most cases. Distinguishing true gynaecomastia (glandular tissue) from pseudogynaecomastia (fatty tissue deposition) is an important clinical step, as the latter is not hormonally driven.

When to Speak to Your GP or Pharmacist

Seek prompt GP advice if breast swelling is unilateral, associated with a firm lump, nipple discharge, or skin changes, as NICE NG12 recommends urgent two-week-wait referral for males with suspicious breast findings.

If you are taking furosemide and notice breast swelling, tenderness, or enlargement, it is sensible to seek advice from your GP or pharmacist, even though a direct causal link with furosemide has not been firmly established. Early assessment helps to identify any underlying cause that may require treatment and provides reassurance where appropriate.

You should contact your GP promptly if you experience:

• Unilateral (one-sided) breast swelling or a firm, irregular lump

• Nipple discharge (particularly bloody or blood-stained), nipple retraction or inversion, or skin changes such as dimpling

• Axillary (armpit) lymph node swelling

• Breast pain that is persistent or worsening

• Rapid onset of breast enlargement

• Any associated symptoms such as unexplained weight loss, fatigue, or testicular changes

These features may warrant further investigation to exclude breast malignancy or an underlying endocrine or testicular condition. In line with NICE NG12 (Suspected Cancer: Recognition and Referral), males presenting with a unilateral, firm subareolar mass — with or without skin or nipple changes — should be considered for urgent referral via the two-week-wait pathway. A palpable testicular mass should similarly prompt an urgent two-week-wait urology referral under NICE NG12.

For milder, bilateral, and gradual breast changes in a patient on multiple medicines, a pharmacist can conduct a structured medication review to identify likely causative agents and liaise with the prescribing GP to consider whether any medicines can be substituted or doses adjusted. It is important that patients do not stop furosemide or any prescribed diuretic without medical advice, as abrupt discontinuation in heart failure or cirrhosis can lead to dangerous fluid accumulation. Open communication with your healthcare team is always the safest approach.

Managing Gynaecomastia While Continuing Necessary Treatment

Management begins with a structured medication review and hormonal investigations; if furosemide cannot be stopped, watchful waiting, substitution of more strongly implicated agents, or specialist-led off-label treatment with tamoxifen may be considered.

For many patients, furosemide is an essential medicine that cannot simply be discontinued. Gynaecomastia, even when drug-related, can often be managed effectively without stopping the causative or suspected medicine, particularly when the underlying condition being treated poses a greater clinical risk.

Initial management steps typically include:

• A thorough medication review to identify and, where possible, substitute more strongly implicated agents (for example, replacing spironolactone with eplerenone, which carries a lower risk of gynaecomastia, subject to clinical suitability and local formulary guidance)

• Hormonal investigations, including serum testosterone, oestradiol, luteinising hormone (LH), follicle-stimulating hormone (FSH), prolactin, and thyroid function tests, to exclude an endocrine cause

• Liver and renal function tests to assess for underlying organ dysfunction contributing to hormonal imbalance

• Testicular ultrasound if a testicular cause is suspected

If gynaecomastia is confirmed as drug-related and the offending medicine cannot be changed, watchful waiting is appropriate in mild cases, as some degree of spontaneous resolution can occur. It is worth noting that medical treatment is generally more effective in the early, tender phase of gynaecomastia (typically within approximately six to twelve months of onset); long-standing gynaecomastia in which fibrous tissue has replaced glandular tissue responds less well to pharmacological intervention.

For persistent or distressing gynaecomastia, short-term pharmacological options such as tamoxifen (an oestrogen receptor modulator) or raloxifene have been used off-label with some evidence of benefit. These are not licensed for this indication, require specialist input, and access is subject to local NHS formulary policies, which vary across England, Scotland, Wales, and Northern Ireland. Patients should discuss these options with an endocrinologist or relevant specialist.

In longstanding cases where fibrous tissue predominates, surgical referral (subcutaneous mastectomy) may be considered. Patients should be supported throughout this process with clear information and, where appropriate, referral to an endocrinologist or breast surgeon. The overarching principle is to balance the clinical necessity of diuretic therapy against the patient's quality of life and wellbeing, in line with NICE CKS guidance on gynaecomastia management.

Frequently Asked Questions